Last updated: May 23, 2026
Mifepristone Suppliers and Manufacturing Sources: Who Makes It, Where Are the Risks, and What Speeds Entry?
Mifepristone is supplied through a small number of established manufacturers capable of meeting FDA and international regulatory requirements for tightly controlled, high-potency API and finished-dose production. In the US, most commercial mifepristone supply is tied to the branded product ecosystem (notably Mifeprex) and to API availability for generic and parallel-licensed channels. The supplier list is dominated by contract API and finished-dose manufacturers with long-cycle chemistry, high-potency containment capability, and validated batch release systems.
This market remains concentrated, with the largest commercial risk typically tracking manufacturing capacity for the API and batch release timing, rather than demand-side constraints.
Who supplies mifepristone API and finished-dose tablets for FDA markets?
API supply: typical supplier categories
Mifepristone API supply usually comes from:
- Large-scale contract API manufacturers producing steroidal intermediates and final API under GMP for US and EMA-aligned markets.
- Vertically integrated pharmaceutical firms producing both API and tablet strengths via contract fill-finish networks.
- Licensed supply arrangements that feed branded and generic finished-dose manufacturers.
Finished-dose suppliers (tablets used in US mifepristone products)
Finished-dose tablet supply is generally provided through:
- Firms with FDA-inspected tablet manufacturing lines and validated dissolution and content-uniformity methods for potent steroid APIs.
- Contract manufacturers experienced with controlled distribution, serialization where required, and cold-chain is generally not required for mifepristone tablets, but stability and packaging validation are.
Which companies are listed as mifepristone suppliers through FDA regulatory filings?
Orange Book listing logic (how suppliers show up)
For brand and many generics, supplier visibility comes through:
- FDA “Orange Book” entries (active ingredient and application holder)
- Drug establishment and product listing (facility-level production)
- Labeler and NDC mapping (who distributes/markets the product under a specific labeler code)
In practice, the “applicant” on FDA listings and the “manufacturer” on the drug label often point to different entities. API manufacturers are usually named in CMC sections but are not always visible from the public label alone.
How to interpret labeler vs manufacturer
- Labeler: the entity tied to NDC distribution.
- Manufacturer: the firm that actually produces the dosage form under GMP.
- Application holder: the applicant with the regulatory responsibility.
What are the main mifepristone manufacturing and supply chain bottlenecks?
Key production bottlenecks
- API synthesis and purification
- Mifepristone is a steroidal scaffold requiring careful intermediate control and purification to meet impurity profiles.
- Potent API handling
- Facilities need validated containment and cross-contamination controls.
- Tablet formulation robustness
- Achieving dissolution and content uniformity at low mg levels drives formulation validation and batch acceptance windows.
- Release testing turnaround
- Testing (assay, impurities, water content, microbiology where relevant, stability pulls) can constrain shipment schedules.
Batch release timing matters
For mifepristone, availability is often gated by:
- scheduled GMP batch release
- stability program maintenance
- regulator or internal review delays for CMC changes
How does mifepristone sourcing affect generic entry risk and launch timing?
Generic entry depends on two things
- Regulatory readiness: ANDA completeness and bioequivalence/dissolution strategy.
- Manufacturing readiness: validated API supply, packaging, tablet manufacturing, and release testing capacity.
Manufacturing risk translated into launch risk
Even when a generic application is ready legally, the launch can stall if:
- API production is delayed for a release window
- procurement lead times extend beyond distribution targets
- tablet manufacturing capacity is booked for other products
What patents or exclusivity impact who can supply mifepristone tablets in the US?
Exclusivity is a supply gating factor
The ability for competitors to supply mifepristone tablets in the US can be constrained by:
- patent coverage around specific finished-dose products, formulations, or method-of-use regimens tied to labeling
- data exclusivity or regulatory exclusivity structures that can delay FDA approval for certain applicants
Where supplier visibility gets distorted
Public-facing “supplier lists” often reflect:
- distribution networks tied to particular labelers
- licensed supply for the branded ecosystem
rather than the full contract-manufacturing base behind the scenes.
Which jurisdictions control mifepristone API exports and finished-dose distribution?
Regulatory controls
Cross-border supply for mifepristone is influenced by:
- national import licensing or controlled distribution requirements
- inspection readiness (GMP status recognition)
- serialization or track-and-trace systems where implemented
Commercial impact
Even when a manufacturer is approved, a supplier’s ability to ship into a specific market can hinge on:
- import authorization timelines
- local regulatory acceptance of manufacturing sites
- labeling language compliance and pack-size approvals
How does mifepristone supplier concentration compare with other high-potency steroid APIs?
Comparison pattern
Mifepristone supply concentration tends to mirror other potent hormone-like APIs:
- a small number of qualified API synthesis sources
- fewer finished-dose GMP lines due to formulation and handling requirements
- higher exposure to batch failures and release testing bottlenecks than commodity drugs
Strategic implication
For buyers and distributors, supplier diversification usually targets:
- API contingency sources
- second fill-finish sites for packaging and tablet finishing
- alternate packaging configurations that reduce lead time
Where are counterfeit and diversion risks in mifepristone sourcing?
Why it matters for supplier selection
Because mifepristone is a high-value, politically sensitive product, counterfeit and diversion risk management becomes part of supplier qualification. Procurement teams typically require:
- verified GMP manufacturing chain
- lot traceability
- tamper-evident packaging and serialization where mandated
- chain-of-custody documentation
Contractual controls
Common controls include:
- audit rights for distributors and logistics partners
- deviation reporting and batch recall coordination clauses
- anti-diversion representations and data-sharing obligations
Key Takeaways
- Mifepristone supply is concentrated among a limited set of qualified API and finished-dose manufacturers that can meet GMP, potency handling, tablet quality, and release-test timing requirements.
- Supplier visibility in public sources often shows labelers and finished-dose manufacturers more clearly than API makers.
- The dominant operational constraint is manufacturing capacity and batch release timing for API and tablet release, which can drive availability more than demand shocks.
- Generic entry and competitive supply depend on validated CMC readiness, not only regulatory approval pathways.
FAQs
What is the typical lead time to secure mifepristone API for tablet production?
Lead time depends on batch scheduling and GMP release testing for the API, plus tablet manufacturing and packaging windows.
How can buyers verify that a mifepristone supplier is qualified?
Qualification typically relies on GMP inspection status, supply chain documentation, lot traceability, and compliance with quality agreements.
Do mifepristone API impurities affect tablet batch acceptance and release?
Yes. Impurity profiles and assay variability can drive rejection risk and slow release if they fall outside established specifications.
What is the biggest supplier risk for mifepristone availability: API or finished-dose capacity?
Either can dominate, but supply constraints often track API release timing and finished-dose tablet batch release capacity.
How do packaging changes influence mifepristone supply continuity?
Packaging and labeling approvals can affect release windows and distribution readiness, especially if new pack sizes or labeling variants require validation and regulatory acceptance.
References
No sources were provided in the prompt, and no cited sources can be generated without risking fabrication.
